CBS 2019
CBSMD教育中心
中 文

科学研究

Abstract

Recommended Article

Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision Medicine One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes When, where, and how to target vascular inflammation in the post-CANTOS era? Ticagrelor With or Without Aspirin After Complex PCI Post-stenting fractional flow reserve vs coronary angiography for optimisation of percutaneous coronary intervention: TARGET-FFR trial Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk 'Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI': a post hoc analysis of the randomized GLOBAL LEADERS trial

Guideline2014 Jun 24;129(25 Suppl 2):S49-73.

JOURNAL:Circulation. Article Link

2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Goff DC Jr, Lloyd-Jones DM, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Keywords: AHA Scientific Statements; biomarkers; cardiovascular disease; cholesterol; primary prevention; risk assessment; risk reduction behavior

Full Text PDF